Tema Neuroscience And Mental Health ETF
MNTL
NASDAQ Global Market- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Tema Neuroscience and Mental Health ETF (MNTL) is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing primarily in global equity securities of companies addressing central nervous system disorders and mental health conditions; its portfolio spans pharmaceuticals, emerging biotechs, medical devices, diagnostics, therapeutics, clinical products, and healthcare services across established and innovative firms worldwide. The ETF employs a combination of top-down sector analysis and bottom-up stock selection, targeting 15 to 100 pure-play companies in neuroscience and psychiatry, including those developing disease-modifying treatments for Alzheimer's disease, genetic therapies for rare neurological disorders, precision mental health solutions, and non-opioid pain therapies. MNTL trades on Nasdaq with a net expense ratio of 0.75%, inception date of January 22, 2024, and is part of the Tema ETF suite managed by portfolio manager David K. Song, MD, PhD, CFA, under the advisory of Tema Global Limited, a New York-based firm founded in 2022–2023 and headquartered at Brookfield Place. Geographically, the fund provides exposure to companies operating in the United States, Europe, Japan, and other global markets, serving institutional and retail investors focused on thematic healthcare innovation. In a significant recent development approved by the Board of Trustees of the Tema ETF Trust on June 26, 2025, MNTL faces liquidation, marking a major operational change amid ongoing advancements in its targeted therapeutic areas such as Alzheimer's rollouts and RNA-based CNS therapies highlighted in Tema's 2025 Healthcare Outlook.